{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-030127","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.852584+00:00","generated_at":"2026-06-18T08:42:29.865960+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"MTAC amends term sheet with Magnetar, increasing expense reimbursement cap to $600K","bullets":["Amendment raises Magnetar's expense reimbursement cap from $300,000 to $600,000 for the proposed $50M convertible note financing.","Notes are 8.0% senior secured convertible notes concurrent with the TriSalus business combination.","Financing is contingent on closing of the business combination with TriSalus Life Sciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-030127","json":"https://secwatch.observer/filing/0001104659-23-030127.json","markdown":"https://secwatch.observer/filing/0001104659-23-030127.md","text":"https://secwatch.observer/filing/0001104659-23-030127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923030127/0001104659-23-030127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923030127/tm238778d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:42:29.865960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c37d4cc96e8deb5b8cffaac42ebbeee61263067","claim":"TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MedTech Acquisition Corporation valued at Merger with TriSalus surviving as wholly owned subsidiary; TriSalus equity holders receive MTAC comm (effective 2022-11-11).","evidence_excerpt":"On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“ MTAC ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “ Merger ”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923030127/0001104659-23-030127-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"MedTech Acquisition Corporation"},{"label":"Value","value":"Merger with TriSalus surviving as wholly owned subsidiary; TriSalus equity holders receive MTAC comm"},{"label":"Effective","value":"2022-11-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}